Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal

(Reuters) -Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.

(Reporting by Sneha S K; Editing by Krishna Chandra Eluri)